Predictive Oncology EBITDA 2010-2025 | POAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$44.5B
Doximity (DOCS)	$12.8B
Tempus AI (TEM)	$12.8B
Hims & Hers Health (HIMS)	$10B
IRhythm Technologies (IRTC)	$5.5B
Hinge Health (HNGE)	$4.5B
Inspire Medical Systems (INSP)	$2.7B
Privia Health (PRVA)	$2.7B
Heartflow (HTFL)	$2.6B
Phreesia (PHR)	$1.9B
10x Genomics (TXG)	$1.8B
Enovis (ENOV)	$1.7B
Omnicell (OMCL)	$1.5B
Schrodinger (SDGR)	$1.5B
Azenta (AZTA)	$1.4B
Clover Health Investments (CLOV)	$1.3B
Claritev (CTEV)	$1.2B
Evolent Health (EVH)	$1.1B
Fulgent Genetics (FLGT)	$674M
Zepp Health (ZEPP)	$550M
Veradigm (MDRX)	$534M
Standard BioTools (LAB)	$493M
Talkspace (TALK)	$445M
Butterfly Network (BFLY)	$410M
Carlsmed (CARL)	$363M
TruBridge (TBRG)	$300M
Health Catalyst (HCAT)	$257M
Outset Medical (OM)	$247M
SOPHiA GENETICS SA (SOPH)	$224M
Nyxoah SA (NYXH)	$214M